Jeffrey Cohen, MD

Director, Mellen Center for Multiple Sclerosis Treatment and Research; Director, Experimental Therapeutics Program, Cleveland Clinic

Articles

Gearing Up For the 2022 ACTRIMS Forum: Jeffrey Cohen, MD

February 24, 2022

The professor of neurology at Cleveland Clinic and president of ACTRIMS noted his excitement for this year’s Forum, which will feature presentations on a variety of topics in the field of multiple sclerosis. [WATCH TIME: 2 minutes]

Major Themes, Focuses at ACTRIMS 2022

February 11, 2022

Jeffrey Cohen, MD, director, Mellen Center for MS Treatment and Research, Cleveland Clinic; and president, ACTRIMS, discussed what he is looking forward to at the 2022 ACTRIMS Forum, as well as the overarching themes of the meeting. [WATCH TIME: 2 minutes]

Grading Valuable Aspects of Mesenchymal Cell Activity in Progressive MS: Jeffrey Cohen, MD

October 14, 2021

The director of the Mellen Center for MS Treatment and Research at Cleveland Clinic provided context on whether efficacy outcomes should be weighed more than mechanistic action when evaluating MSC-NTF cell therapies. [WATCH TIME: 3 minutes]